Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-09. Numbers and descriptions here follow the published literature rather than marketing material.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
For four months, as liability issues were resolved, American blepharospasm patients traveled to Canadian eye centers for their injections. Based on data from thousands of people collected by 240 investigators, Oculinum Inc (which was soon acquired by Allergan) received FDA approval in 1989 to market Oculinum for clinical use in the United States to treat adult strabismus (crossed eyes) and blepharospasm (uncontrollable blinking). Allergan then began using the trademark Botox. This original approval was granted under the 1983 US Orphan Drug Act.
=== Public response === Public debate in the Singaporean news media on the death penalty is almost non-existent, although the topic is occasionally discussed in the midst of highly publicised criminal cases. Efforts to garner public opinion on the issue are rare, although it has been suggested that the population is influenced by a legalist philosophy which holds that harsh punishment deters crime and helps maintain social peace and harmony. In October 2007, Senior Minister of State for Law and Home Affairs Ho Peng Kee said in Parliament that "Certain of us may hold the view that the death penalty should be abolished. But in a survey done two years ago, reported in the Straits Times, 95% of Singaporeans feel that the death penalty should stay. This is something which has helped us to be safe and secure all these years and it is only reserved for a very few select offences." Joshua Benjamin Jeyaretnam, an opposition Member of Parliament, was reportedly only given a few minutes to speak in Parliament on the issue before his comments were rebutted by Ho Peng Kee. There were a few instances where in certain high-profile cases, the public would argue for the death penalty to be imposed on those who allegedly committed murder.
White sharks range from tropical to temperate and even colder waters around the world with major populations in northwestern and northeastern Pacific, western North Atlantic, the Mediterranean, southern African waters and Oceania. It is also present near the coasts of South America but appears to be uncommon. Shark expert Greg Skomal lists the Farallon Islands, California; Guadalupe Island, Mexico; Cape Cod, Massachusetts; Western Cape, South Africa; Neptune Islands, Australia; and both Stewart Island and the Chatham Islands, New Zealand, as major coastal feeding aggregations. Researchers have also identified an offshore feeding aggregation between western North America and Hawaii dubbed the White Shark Café. White sharks can be found both along the coast and in the open ocean. They are typically close to the surface but may dive to depths of up to 1,300 m (4,300 ft). Deeper dives are more common in the open ocean. Coastal habitats used include nearshore archipelagos, offshore reefs, banks and shoals, and headlands. A 2018 study indicated that white sharks will congregate in patches of warm water in the open ocean. Juvenile white sharks are more limited to shallow coastal waters with temperatures between 14 and 24 °C (57 and 75 °F). Increased sightings of young sharks in areas where they were not previously common, such as Monterey Bay on the central California coast, suggest climate change may be forcing juveniles closer to the poles.
1-Methylnicotinamide (1-MNA, trigonellamide) is a prototypic organic cation. 1-Methylnicotinamide is the methylated amide of nicotinic acid (vitamin B3). 1-Methylnicotinamide is an endogenic substance that is produced in the liver when nicotinamide is metabolized. It is a typical substance secreted in the kidney. It participates in the nicotinamide salvage pathway within the NAD+ (nicotinamide adenine dinucleotide) metabolic pathway, thereby contributing to optimizing NAD+ levels.
=== Former commissioners === David Gallop was the initial chief executive officer of the restructured ARL Commission. He was previously the CEO of the NRL and his contract extension to become inaugural ARL CEO was a condition placed by News Limited with the ARL. On 5 June 2012 the ARL announced Gallop's departure from the CEO position and that he would take up a position at the FFA in 2013. David Smith was announced as the new ARL CEO in November 2012, taking charge on 1 February 2013.
Sources: en.wikipedia.org
The Panzergrenadier Division "Großdeutschland", also commonly referred to simply as Großdeutschland or Großdeutschland Division, was an elite combat unit of the German Army (Heer) that fought on the Eastern Front in World War II. Formed in 1921, it was known as the Wachregiment Berlin and served as a ceremonial guard unit until it was in mid-1939 re-equipped for combat, becoming a regiment of the combined Wehrmacht German armed forces. The regiment would later be expanded and renamed Infanterie-Division Großdeutschland in 1942, and after significant reorganization was renamed Panzergrenadier-Division Großdeutschland in May 1943. In November 1944, while the division retained its status as a Panzergrenadier division, some of its subordinate units were expanded to divisional status, and the whole group of divisions were reorganized as Panzerkorps Großdeutschland.
September 15 The US military announces that it destroyed two Iranian small boats the day before following an IRGC attempt to capture one of its Navy drones patrolling the Strait of Hormuz. A federal judge blocks the Kennedy Center from adding President Trump's name to the building or its grounds without congressional approval. Hours later, the centre's board votes to close most of the venue for up to two years for renovations. September 16 Three people are killed in a helicopter crash in Chatsworth, Los Angeles, including NBC News journalists Eliana Moreno and George Marciniw. The Federal Reserve raises interest rates for the first time in three years, from 3.5%-3.75% to 3.75%-4%. A memorandum of understanding is signed with the Pakistan army by US drone maker Powerus, which is set to merge with a firm backed by Trump’s sons. The Trump administration announces that Palestinian president Mahmoud Abbas and his delegation are barred from attending the UN General Assembly in New York, accusing them of breaching US law. September 17 The House of Representatives passes sweeping Russia sanctions legislation by a vote of 262-159. Flash flooding in the Navajo Nation kills three. A UN mission finds grounds to believe that the US committed war crimes in the 2026 Minab school attack and the 2026 Lamerd sports hall attack.
Most modern nuclear weapons utilize 238U as a "tamper" material (see nuclear weapon design). A tamper which surrounds a fissile core works to reflect neutrons and to add inertia to the compression of the 239Pu charge. As such, it increases the efficiency of the weapon and reduces the critical mass required. In the case of a thermonuclear weapon, 238U can be used to encase the fusion fuel, the high flux of very energetic neutrons from the resulting fusion reaction causes 238U nuclei to split and adds more energy to the "yield" of the weapon. Such weapons are referred to as fission-fusion-fission weapons after the order in which each reaction takes place. An example of such a weapon is Castle Bravo. The larger portion of the total explosive yield in this design comes from the final fission stage fueled by 238U, producing enormous amounts of radioactive fission products. For example, an estimated 77% of the 10.4-megaton yield of the Ivy Mike thermonuclear test in 1952 came from fast fission of the depleted uranium tamper. Because depleted (or natural) uranium has no critical mass, it can be added to thermonuclear bombs in almost unlimited quantity. The Soviet Union's test of the Tsar Bomba in 1961 produced "only" 50 megatons of explosive power, over 90% of which came from fusion because the 238U final stage had been replaced with lead. Had 238U been used instead, the yield of the Tsar Bomba could have been well above 100 megatons, and it would have produced nuclear fallout equivalent to one third of the global total that had been produced up to that time.
== Mechanism of action == GLP-1 poly-agonist peptides work by activating two hormone receptors rather than one. The two receptors targeted are both triggered naturally after eating, but they act on different parts of the body and play complementary roles in regulating blood sugar, appetite, and fat metabolism. In the pancreas, both receptors stimulate insulin release in response to elevated blood glucose, but through slightly different cellular pathways. Activating both at once produces a stronger insulin response than either receptor alone. The two receptors also balance each other in their effects on glucagon; GIP raises glucagon when blood sugar is too low, while GLP-1 suppresses glucagon when blood sugar is too high. In fat tissue, GIP promotes the removal of triglycerides from the bloodstream, while GLP-1 encourages fat breakdown through signals sent via the central nervous system. Both hormones also reduce fat build up in the liver and lower insulin resistance.
In addition to functioning as CoA, this compound can act as an acyl group carrier to form acetyl-CoA and other related compounds; this is a way to transport carbon atoms within the cell. CoA is also required in the formation of acyl carrier protein (ACP), which is required for fatty acid synthesis. Its synthesis also connects with other vitamins such as thiamin and folic acid.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.